# Decoy Therapeutics Inc.: financial statements, quarterly

DCOY · Nasdaq · CIK 1615219 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dcoy.md) · [Financials](/companies/dcoy/financials.md) · [Filings](/companies/dcoy/filings.md) · [Insiders](/companies/dcoy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dcoy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-346852.md) | not reported | not reported | not reported | [228](/filings/0001193125-26-346852.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,036](/filings/0001615219-24-000089.md) | [60.0 d](/filings/0001615219-25-000037.md) | [243](/filings/0001615219-25-000048.md) | [214](/filings/0001615219-25-000096.md) | [137](/filings/0001615219-25-000164.md) | [175 d](/filings/0001193125-26-134897.md) | [75.5](/filings/0001193125-26-214816.md) | [116](/filings/0001193125-26-346852.md) | [61.8](/filings/0001615219-25-000164.md) | [114 d](/filings/0001193125-26-134897.md) | [750](/filings/0001193125-26-214816.md) | [1,304](/filings/0001193125-26-346852.md) |
| Operating income | $k | [(2,532)](/filings/0001615219-24-000089.md) | [(971) d](/filings/0001615219-25-000037.md) | [(1,772)](/filings/0001615219-25-000048.md) | [(1,468)](/filings/0001615219-25-000096.md) | [(1,006)](/filings/0001615219-25-000164.md) | [(1,489) d](/filings/0001193125-26-134897.md) | [(1,719)](/filings/0001193125-26-214816.md) | [(966)](/filings/0001193125-26-346852.md) | [(895)](/filings/0001615219-25-000164.md) | [(9,035) d](/filings/0001193125-26-134897.md) | [(2,284)](/filings/0001193125-26-214816.md) | [(2,631)](/filings/0001193125-26-346852.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,443)](/filings/0001615219-24-000089.md) | [(882) d](/filings/0001615219-25-000037.md) | [(1,715)](/filings/0001615219-25-000164.md) | [(1,424)](/filings/0001615219-25-000164.md) | [(972)](/filings/0001615219-25-000164.md) | [(1,464) d](/filings/0001193125-26-134897.md) | [(1,710)](/filings/0001193125-26-346852.md) | [(958)](/filings/0001193125-26-346852.md) | [(873)](/filings/0001615219-25-000164.md) | [(8,978) d](/filings/0001193125-26-134897.md) | [(2,225)](/filings/0001193125-26-346852.md) | [(2,374)](/filings/0001193125-26-346852.md) |
| Diluted EPS | $ per share | [(5.21)](/filings/0001615219-24-000089.md) | not reported | [(3.27)](/filings/0001615219-25-000048.md) | [(2.37)](/filings/0001615219-25-000096.md) | [(11.38)](/filings/0001615219-25-000164.md) | not reported | [(240.07)](/filings/0001193125-26-214816.md) | [(81.21)](/filings/0001193125-26-346852.md) | [(1.81)](/filings/0001615219-25-000164.md) | not reported | [(4.18)](/filings/0001193125-26-214816.md) | [(4.46)](/filings/0001193125-26-346852.md) |
| Basic EPS | $ per share | [(5.21)](/filings/0001615219-24-000089.md) | not reported | [(3.27)](/filings/0001615219-25-000048.md) | [(2.37)](/filings/0001615219-25-000096.md) | [(11.38)](/filings/0001615219-25-000164.md) | not reported | [(240.07)](/filings/0001193125-26-214816.md) | [(81.21)](/filings/0001193125-26-346852.md) | [(1.81)](/filings/0001615219-25-000164.md) | not reported | [(4.18)](/filings/0001193125-26-214816.md) | [(4.46)](/filings/0001193125-26-346852.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.6](/filings/0001615219-23-000071.md) | [5.9](/filings/0001615219-25-000037.md) | [4.4](/filings/0001615219-24-000040.md) | [3.3](/filings/0001615219-24-000071.md) | [3.3](/filings/0001615219-24-000089.md) | [2.4](/filings/0001193125-26-134897.md) | [1.8](/filings/0001615219-25-000048.md) | [0.8](/filings/0001615219-25-000096.md) | [4.8](/filings/0001615219-25-000164.md) | [10.7](/filings/0001193125-26-346852.md) | [7.8](/filings/0001193125-26-214816.md) | [8.3](/filings/0001193125-26-346852.md) |
| Current assets | $m | [8.3](/filings/0001615219-23-000071.md) | [6.5](/filings/0001615219-25-000037.md) | [4.8](/filings/0001615219-24-000040.md) | [3.5](/filings/0001615219-24-000071.md) | [3.8](/filings/0001615219-24-000089.md) | [3.0](/filings/0001193125-26-134897.md) | [2.3](/filings/0001615219-25-000048.md) | [1.4](/filings/0001615219-25-000096.md) | [6.1](/filings/0001615219-25-000164.md) | [11.0](/filings/0001193125-26-346852.md) | [8.4](/filings/0001193125-26-214816.md) | [8.6](/filings/0001193125-26-346852.md) |
| Total assets | $m | [8.4](/filings/0001615219-23-000071.md) | [6.6](/filings/0001615219-25-000037.md) | [4.9](/filings/0001615219-24-000040.md) | [3.6](/filings/0001615219-24-000071.md) | [3.9](/filings/0001615219-24-000089.md) | [3.0](/filings/0001193125-26-134897.md) | [2.3](/filings/0001615219-25-000048.md) | [1.4](/filings/0001615219-25-000096.md) | [6.1](/filings/0001615219-25-000164.md) | [11.1](/filings/0001193125-26-346852.md) | [8.4](/filings/0001193125-26-214816.md) | [9.0](/filings/0001193125-26-346852.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [1.5](/filings/0001193125-26-134897.md) | not reported | not reported | not reported | [5.2](/filings/0001193125-26-346852.md) | [4.5](/filings/0001193125-26-214816.md) | [4.7](/filings/0001193125-26-346852.md) |
| Total liabilities | $m | [2.3](/filings/0001615219-23-000071.md) | [1.3](/filings/0001615219-25-000037.md) | [1.2](/filings/0001615219-24-000040.md) | [1.2](/filings/0001615219-24-000071.md) | [0.9](/filings/0001615219-24-000089.md) | [1.5](/filings/0001193125-26-134897.md) | [2.3](/filings/0001615219-25-000048.md) | [2.2](/filings/0001615219-25-000096.md) | [1.8](/filings/0001615219-25-000164.md) | [5.2](/filings/0001193125-26-346852.md) | [4.5](/filings/0001193125-26-214816.md) | [4.7](/filings/0001193125-26-346852.md) |
| Shareholders' equity | $m | [6.1](/filings/0001615219-24-000089.md) | [5.3](/filings/0001193125-26-134897.md) | [3.6](/filings/0001615219-25-000164.md) | [2.4](/filings/0001615219-25-000164.md) | [2.9](/filings/0001615219-25-000164.md) | [1.5](/filings/0001193125-26-346852.md) | [0.1](/filings/0001193125-26-346852.md) | [(0.8)](/filings/0001193125-26-346852.md) | [4.2](/filings/0001615219-25-000164.md) | [5.9](/filings/0001193125-26-346852.md) | [3.9](/filings/0001193125-26-346852.md) | [4.3](/filings/0001193125-26-346852.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,749) d](/filings/0001615219-24-000089.md) | [(1,511) d](/filings/0001615219-25-000037.md) | [(1,354)](/filings/0001615219-25-000048.md) | [(1,072) d](/filings/0001615219-25-000096.md) | [(1,357) d](/filings/0001615219-25-000164.md) | [(743) d](/filings/0001193125-26-134897.md) | [(1,182)](/filings/0001193125-26-214816.md) | [(862) d](/filings/0001193125-26-346852.md) | [(1,647) d](/filings/0001615219-25-000164.md) | [(1,136) d](/filings/0001193125-26-134897.md) | [(2,889)](/filings/0001193125-26-214816.md) | [(2,652) d](/filings/0001193125-26-346852.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [2,248](/filings/0001615219-23-000071.md) | [2,392](/filings/0001615219-24-000040.md) | [339](/filings/0001615219-24-000071.md) | [469](/filings/0001615219-24-000089.md) | [524](/filings/0001615219-25-000048.md) | [600](/filings/0001615219-25-000096.md) | [85.5](/filings/0001615219-25-000164.md) | [7.1](/filings/0001193125-26-214816.md) | [11.8](/filings/0001193125-26-346852.md) | [482](/filings/0001615219-25-000164.md) | [532](/filings/0001193125-26-214816.md) | [532](/filings/0001193125-26-346852.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 655,185 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346852.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.